CEVOSTAMAB
UNII P86BHN01VE

Substance Identification & Data

This profile provides standardized clinical and technical data for Cevostamab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) P86BHN01VE.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2249888-53-5 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

P86BHN01VE

CAS Registry Number

2249888-53-5

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

CEVOSTAMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C139549

National Cancer Institute reference terminology for clinical and research data.

INN ID

11258

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

HI-201

Identifier assigned by the United States Adopted Names Council.

Substance Type

CEVOSTAMAB

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Cevostamab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

CEVOSTAMAB

Common Names & Synonyms

ANTI-FCRH5/CD3 BITE ANTIBODY BFCR4350A

BFCR4350A (ANTI-FCRH5/CD3 T-CELL DEPENDENT BISPECIFIC ANTIBODY)

CEVOSTAMAB [USAN]

Cevostamab [WHO-DD]

FCRH5/CD3 T CELL DEPENDENT BISPECIFIC ANTIBODY BFCR4350A

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS FC RECEPTOR-LIKE PROTEIN 5, FCRL5 (BXMAS1, FC RECEPTOR HOMOLOG 5, IMMUNE RECEPTOR TRANSLOCATION-ASSOCIATED PROTEIN 2, CD307E-ANTIGEN)) AND ANTI-(HOMO SAPIENS T-CELL SURFACE GLYCOPROTEIN CD3 EPSILON CHAIN, CD3E (LEU-4 EPSILON CHAIN, CD3E-ANTIGEN)), MONOCLONAL ANTIBODY, BISPECIFIC TETRAVALENT;.GAMMA.1 HEAVY CHAIN ANTI FCRL5 (1-450) (VH (MUS MUSCULUS IGHV2-4*01 (77%) (IGHD)-IGHJ3*01 (91%)/HOMO SAPIENS IGHV4-4*08 (73%) (IGHD)-IGHJ5*01 (86%)) (8.7.14) (1-120)-HOMO SAPIENS IGHG1*03 (CH1(R97>K(217)), CH2(N67>G(300)), CH3(T26>W(369))) (121-450) (223-214')-DISULFIDE WITH .KAPPA. LIGHT CHAIN ANTI FCRL5 (1'-214') (V-KAPPA (HOMO SAPIENS IGKV1-39*01 (83%) IGKJ2*01 (92%))(6.3.9) (1'-107')-HOMO SAPIENS IGKC*01 (108'-214')), (229-228'':232-231'')-BISDISULFIDE WITH .GAMMA.1 HEAVY CHAIN ANTI CD3 (1''-449'') (VH (HOMO SAPIENS IGHV1-3*01 (83%) (IGHD)-IGHJ4*01)) (8.8.12) (1''-119'')-HOMO SAPIENS IGHG1*03 (CH1(R97>K(216'')), CH2(N67>G(299'')), CH3(T26>S(368''), L28>A(370''), Y67>W(409''),)) (120''-449'') (222''-219''')-DISULFIDE WITH .KAPPA. LIGHT CHAIN ANTI CD3 (1'''-219''') (V-KAPPA (HOMO SAPIENS IGKV4-1*01 (89%) IGKJ1*01)) (12.3.8) (1'''-112''')-HOMO SAPIENS IGKC*01 (113'''-219''')); PRODUCED IN CHO CELLS

RECOMBINANT ANTI-FCRH5 X ANTI-CD3 BI-SPECIFIC T-CELL ENGAGER BFCR4350A

cevostamab [INN]

Systematic Nomenclature

IMMUNOGLOBULIN G1 (300-GLYCINE,369-TRYPTOPHAN), ANTI-(HUMAN FC RECEPTOR-LIKE PROTEIN FCRL5) (HUMAN-MUS MUSCULUS MONOCLONAL KFCR8534A .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL KFCR8534A .KAPPA.-CHAIN, DIMER WITH IMMUNOGLOBULIN G1 (299-GLYCINE,368-SERINE,370-ALANINE,409-VALINE), ANTI-(HUMAN CD3 ANTIGEN) (HUMAN-MUS MUSCULUS MONOCLONAL HCDT4425A .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL HCDT4425A .KAPPA.-CHAIN

SYS